Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBITDA (2020 - 2025)

Historic EBITDA for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$15.8 million.

  • Foghorn Therapeutics' EBITDA rose 1434.54% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year increase of 1855.91%. This contributed to the annual value of -$85.7 million for FY2024, which is 1008.44% up from last year.
  • Per Foghorn Therapeutics' latest filing, its EBITDA stood at -$15.8 million for Q3 2025, which was up 1434.54% from -$18.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year EBITDA high stood at -$13.5 million for Q3 2023, and its period low was -$29.4 million during Q1 2023.
  • Over the past 5 years, Foghorn Therapeutics' median EBITDA value was -$23.1 million (recorded in 2021), while the average stood at -$23.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 6465.74% in 2021, then soared by 5073.97% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' EBITDA (Quarter) stood at -$29.1 million in 2021, then rose by 3.88% to -$28.0 million in 2022, then rose by 17.74% to -$23.0 million in 2023, then grew by 14.37% to -$19.7 million in 2024, then increased by 20.01% to -$15.8 million in 2025.
  • Its last three reported values are -$15.8 million in Q3 2025, -$18.0 million for Q2 2025, and -$19.0 million during Q1 2025.